The dramatic bidding war kicked off last week with Novo's surprise play for Metsera, which had already agreed to be acquired ...

Pfizer plans to sweeten its bid for Metsera , a person familiar with the matter told Reuters, after a judge denied its ...

The Trump administration is expected to announce deals with Eli Lilly and Novo Nordisk to cut prices of some weight loss ...

Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court's decision denying Pfizer's request for a temporary restraining order to prevent Metsera, Inc.

Health-care companies rose amid mixed earnings. Danish obesity-drug maker Novo Nordisk slid after it lowered its sales projection due to intensifying competition, pricing pressure and copycat versions ...

The Trump administration is negotiating an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their weight loss drugs at a lower price through TrumpRx, sources ...

Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that ...

Novo Nordisk's $10 billion bid for Metsera, an obesity drug developer, is embroiled in legal scrutiny over potential U.S. antitrust law violations. As Pfizer and Novo vie for Metsera, the FTC warns of ...

Recent health sector updates reveal Humana's shaky investor confidence due to lack of 2026 forecasts despite higher profits, ...

Amid the rapidly unfolding saga revolving around Metsera, a judge has denied Pfizer’s request to block Novo Nordisk’s buyout ...

The Federal Trade Commission has raised concerns about Novo Nordisk’s attempt to outbid Pfizer to acquire obesity startup ...

SmartScripts has faced a welter of lawsuits and been fined for its sale of a counterfeit version of popular weight-loss drug ...